يعرض 181 - 200 نتائج من 21,342 نتيجة بحث عن '(( significant decrease decrease ) OR ( significant teer decrease ))', وقت الاستعلام: 0.41s تنقيح النتائج
  1. 181

    Decreased synthesis of VCAM-1, tubulin and dynein proteins in the heart of mice stimulated with EVs (green) or ICs (blue). حسب Alberto Cornet-Gomez (10676133)

    منشور في 2025
    "…The values represent the mean ± SEM, with significance set at p < 0.05 (*).</p>…"
  2. 182
  3. 183
  4. 184
  5. 185
  6. 186
  7. 187
  8. 188

    NgR1 KO mice exhibited an increase in excitatory synapses and a decrease in inhibitory synapses, indicating an imbalance of synaptic transmission. حسب Jinwei Zhang (462455)

    منشور في 2025
    "…The inhibitory synaptic density of NgR1 mice showed a significant decrease when compared to WT mice (***P <  0.001). …"
  9. 189
  10. 190
  11. 191
  12. 192
  13. 193

    Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> حسب Razia Rashid Rahil (22772495)

    منشور في 2025
    "…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P<sub>i</sub>-induced VSMCs. …"
  14. 194
  15. 195
  16. 196

    Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx حسب Tengxiang Zhao (20749475)

    منشور في 2025
    "…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…"
  17. 197

    Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx حسب Tengxiang Zhao (20749475)

    منشور في 2025
    "…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…"
  18. 198
  19. 199
  20. 200